Immune checkpoint inhibitors targeting the programmed cell death protein-1/programmed death ligand-1 (PD-1/PD-L1) pathway and the cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) pathway are the two most studied immunotherapy mechanisms in HCC [53]. This evidence concerns the gene PDCD1 and hepatocellular carcinoma.